Nanmo Biology: Net profit of 32.4313 million yuan in 2025, a year-on-year increase of 399.29%

Nanmo Biotechnology released its performance report, achieving an operating income of 421 million yuan in 2025, an increase of 10.50% year-on-year; net profit of 32.4313 million yuan, an increase of 399.29% year-on-year. During the reporting period, signs of recovery appeared in the domestic biopharmaceutical industry, with the company's industrial end operating income increasing compared to the same period last year. The company continued to strengthen cost control and improve operational efficiency by adjusting cage layouts, controlling purchase prices, and optimizing business processes, further reducing costs. At the same time, non-recurring income such as government subsidies increased year-on-year.